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Abstract This article describes pertinent aspects of
histochemical and molecular changes of the human
pituitary adenomas. The article outlines individual tumor
groups with general, speciWc and molecular Wndings. The
discussion further extends to the unusual adenomas or
carcinomas. The description in this article are pertinent
not only for the practicing pathologists who are in the
position of making proper diagnosis, but also for the pitui-
tary research scientists who engage in solving basic
problems in pituitary neoplasms by histochemistry and
molecular biology.
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Introduction
The pituitary adenomas are either clinically functioning
adenomas or non-functioning adenomas. The former
includes GH secreting (cell) adenomas (abbreviated as
GHomas), prolactin (PRL) secreting (cell) adenomas
(PRLomas), TSH secreting (cell) adenomas (TSHomas),
ACTH secreting (cell) adenomas (ACTHomas), and FSH
secreting (cell) adenomas (FSHomas) (Fig. 1). LHomas
are rather rare. Frequent adenomas among these are
GHomas and PRLomas, the remaining tumors are rather
rare. The rest of the adenomas are clinically “non-func-
tioning”. It should be particularly emphasized that major-
ity of clinical nonfunctioning adenomas have been
disclosed to be positive of gonadotropin subunits (SUs).
The WHO ClassiWcation of the Endocrine Tumors fol-
lows this concept (Table 1). Except for ACTHomas, the
pituitary adenomas are usually macroadenomas (Fig. 2).
Sometimes, supra-sellar extension and downward sinus
invasion are observed. Very occasionally, the pituitary
adenomas can occur ectopically most frequently in the
sphenoid sinuses. Pituitary carcinoma is very rare. Meta-
static carcinoma to the pituitary is sometimes seen, its
autopsy Wndings are not extremely rare and common pri-
mary sites include carcinoma of the lung. The pertinent
diagnostic features and characteristics are described
pointing out (1) general Wndings, (2) speciWc Wndings, (3)
non-surgical therapy and therapy-related changes and (4)
molecular Wndings.
Since Rosenfeld et al. (Nelson et al. 1988; Sornson et al.
1996) and Karin et al. (Bodner et al. 1988) reported the cloning
of pituitary-speciWc transcription factor-1 (Pit-1), or
POU1F1 or GHF-1, many transcription factors have been
reported and it is generally known that the functional diVer-
entiation of the pituitary cells are dependent on the combi-
nation of transcription factors and co-factors (Fig. 3). It has
been also known that the human pituitary cells show the co-
localization of GH and SU in the normal condition and
GHomas (Osamura 1988) (Table 2).
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GH-producing (cell) adenoma (GHomas)
General Wndings
It has been well documented that GHomas, which are
secreting growth hormone in excess show two clinically
related phenotypes, acromegaly and gigantism, depending
on patient age at the onset of disease. In immunohisto-
chemistry (IHC), it shows many GH positive tumor cells
(Fig. 4b) and frequently, the tumor cells are also positive
for PRL (Fig. 4c) and -glycoprotein subunit (SU)
(Fig. 4d). The remaining hormones are also occasionally
positive but ACTH is very rare. GHomas can classify, into
Wve distinct adenomas (DeLellis et al. 2004; Vidal et al.
2004). The distinctions can aVect the medical treatment in
the event of surgeries (Bhayana et al. 2005; Ezzat et al.
1995), therefore accurate classiWcation is very important.
Of the Wve types, two are pure GH producing tumors, con-
sisting of monomorphous GH cell are densely granulated,
and sparsely granulated somatotroph adenomas. The others
are plurihormonal tumors that include mammosomatotroph
adenomas, mixed somatotroph–lactotroph adenomas, and
acidophil stem cell adenomas (Vidal et al. 2004). By elec-
tron microscopy, many tumors are the type of “densely
granulated cells” which contain many dense cored numer-
ous secretory granules. Densely granulated adenomas
(DGAs) are composed of large or medium size, round or
polyhedral acidophilic cells with numerous secretory gran-
ules (400–500 nm) in the cytoplasm, and shows strong, uni-
form and diVuse cytoplasmic immunoreactivity for GH
(Fig. 5a). DGA type, <3% of nuclei are MIB-1 positive,
and known to be slow growing and reactively non invasive
(DeLellis et al. 2004; Hagiwara et al. 2003). Sparsely granu-
lated adenomas (SGAs) composed of small round, partly
irregular cell harboring a round nucleus with conspicuous
nucleoli. They have relatively a fewer secretory granules
(100–250 nm). The cells are chromophobic, and immunore-
activity for GH is weak (Fig. 5b). These types of adenomas
are aggressive, and varying degrees of nuclear and cellular
pleomorphism are seen (Horvath et al. 1997). Fibrous bod-
ies are feature for this type of adenoma as mentioned
below. Mammosomatotroph adenomas are morphologically
close to densely granulated somatotroph adenoma and con-
tain abundant and large secretory granules reaching up to
1,500 nm. IHC shows single cell type reactive for both GH
and PRL. Mixed somatotroph–lactotroph adenomas are
most commonly consisting of densely granulated somato-
tropes and sparsely granulated lactotropes. Histologically,
the adenomas consist of acidophilic cells interspersed with
chromophobic. IHC elucidate that GH and PRL are immu-
nostained in diVerent cell populations.
SpeciWc Wndings
Fibrous (keratin) bodies
In some GHomas, the tumor cells contain perinuclear glo-
bules of keratin by IHC. These globules have been called as
Wbrous bodies or recently keratin bodies. Fibrous bodies are
strongly reactive for low molecular weight cytokeratins,
particularly keratin 8 (DeLellis et al. 2004). Immunohisto-
chemical staining conWrms that the globules are composed
of an admixture of intermediate Wlaments and smooth endo-
plasmic reticulum, are located in the Golgi region, and
often indents the nucleus (Neumann et al. 1985; Vidal et al.
Fig. 1 Pathological diagnosis in pituitary adenomas. A total of 382
pituitary adenomas are classiWed with functional classiWcations using
histology, IHC, ultrastructural features as well as biochemical,
imaging and surgical Wndings in surgical resection at Nippon Medical
School since 1977. The tumor cells in FNA are positive for gonadotro-
pin SU, and belonging to gonadotropin producing adenoma
Non−functioning 
adenomas
GHomas
PRLomas
ACTHomas
FSHomas
TSHomas
Others
Total
cases
382
31.5%
26.8%
17.8%
7.7%
4.4%
1.2%
10.6%
(NFA)
Table 1 ClassiWcation of pituitary tumors, 2004 (WHO)
GH producing adenoma Gonadotropin producing adenoma
Densely granulated adenoma Unusual plurihormonal adenoma
Sparsely granulated adenoma Silent subtype 3 adenoma
Mixed adenoma
Mammosomatotroph adenoma Null cell adenoma
Acidophilic stem cell adenoma Hormone immuno-negative 
adenoma
PRL producing adenoma Oncocytoma
Densely granulated adenoma
Sparsely granulated adenoma Others
Acidophilic stem cell adenoma Carcinoma
TSH producing adenoma Atypical adenoma
ACTH producing adenoma
Silent ACTH cell adenoma
Subtype 1
Subtype 2Histochem Cell Biol (2008) 130:495–507 497
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2004) (Fig. 6d). Fibrous bodies are the feature of sparsely
granulated somatotroph adenoma type. The more granu-
lated adenomas, including mammosomatotrophs and pluri-
hormonal lesions, identiWes some perinuclear keratin
(Fig. 6c), but the sparsely granulated adenomas clearly dec-
orates globules of keratin by immunostainig using CAM
5.2 keratin (CK8) (Fig. 6a–b).
Stellate amyloid
Very occasionally, GHomas show “stellate” amyloid
among the tumor cells. The amyloid is positive for Congo
red and is birefringent. By electron microscopy, the amy-
loid is composed of bundles of Wne Wlaments, which appear
to be typical for the amyloid of other origin and nature.
Immunohistochemically, the tumor cells are strongly posi-
tive for GH and the amyloid is also weakly positive for GH
(Osamura et al. 1982).
Fig. 2 A pie chart of the ratio of 
pituitary macro and micro ade-
nomas. Pituitary adenomas are 
ordinary macroadenomas except 
for ACTHomas
Fig. 3 Human pituitary cell lin-
age. Pituitary-speciWc or related 
transcription factors involved in 
the development of pituitary 
gland. SU is expressed in some 
of the normal human GH-pro-
ducing cells and some cases of 
GH-producing adenomas as it 
occurs in mice
Table 2 ImmunoproWle of hormones in pituitary adenomas (%)
* Non-functioning adenomas including 37.6% null cell adenomas
GH PRL ACTH FSH LH TSH SU
GHomas (69 cases) 100 82.6 1.5 4.3 1.5 2.9 56.5
TSHomas (6 cases) 83.3 83.3 16.7 0 0 100 83.3
FSHomas (11 cases) 0 27.3 18.2 100 9.1 63.6 100
PRLomas (27 cases) 3.7 100 0 0 3.7 3.7 3.7
ACTHomas (15 cases) 6.7 13.3 100 0 6.7 0 33.3
NFomas* (197 cases) 4.6 10.2 5.1 42.6 19.8 2.0 43.1
Total 325 cases498 Histochem Cell Biol (2008) 130:495–507
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Changes induced by Octoreotide
In GHoma, treatment with long-acting somtostatin analogs
(SSAs) called octreotide (SMS 201–995) results in reducing
blood GH level, and tumor shrinkage in 40–50% of patients,
especially in those with receptor for somatostatin (Ezzat
et al. 1992; Kovacs and Horvath 2005). Octreotide has high
aYnity for somatostatin receptor (SSTR) 2 and SSTR5.
Takei et al. (2007) determined the expression of SSTR2 and
SSTR5 by IHC and compared this with the results of octreo-
tide suppression testing before surgery to deWne whether
IHC of SSTR could be associated with the preoperative
response to octreotide. They concluded that the percentage
of cell membrane immunopositive for SSTR2 is associated
with the hormone inhibitory eVect, so immunohistochemi-
cal analysis of SSTR in GHoma could provide important
information for predicting the likelihood of successfully
employing SSAs in adjuvant therapy (Fig. 4f).
Fig. 4 GH producing (cell) adenoma (GHoma). The tumor cells of
hematoxylin eosin (H&E) staining (a). In IHC, it shows many GH posi-
tive tumor cells (b), frequently cells are also positive for PRL (c) and
SU (d). The IHC of pituitary-speciWc transcription factor 1 (Pit-1),
which regulate the functional diVerentiation of GH–PRL–TSH cell
lineage (e). In electron microscopy, many GHoma are type of densely
granulated cells, which contain many dense cored numerous secretory
granules (f). SSTR2a is immunostained in cell membrane (g), which
provides important information for SSAs therapy
Fig. 5 The IHC of GH of dense-
ly and sparsely granulated ade-
nomas. Densely granulated 
adenoma shows strong and di-
Vuse cytoplasmic immunoreac-
tivity for GH (a). Sparsely 
granulated adenomas show weak 
GH immunostaining (b)Histochem Cell Biol (2008) 130:495–507 499
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Silent somatotroph adenomas
These are the pituitary adenomas without clinical symp-
toms but show positive for speciWc hormones by IHC in the
individual tumor cells. Silent somatotroph adenoma
expresses GH and its mRNA without evidence of acro-
megaly (Naritaka et al. 1999).
Molecular Wndings
According to the previous studies on the functional devel-
opment of the pituitary adenomas, it has been clariWed that
the functioning pituitary adenomas generally follows the
combination of transcription factors and co-factors which
have been known to function in the physiologic condition
(Minematsu et al. 2005; Sanno et al. 2001). For example,
GHomas are regulated by Pit–1 (Fig. 4e), which regulate
the functional diVerentiation of GH–PRL–TSH cell lineage
(Lee et al. 2005; Miyai et al. 2005) and positive in the
nuclei of many tumor cells, and growth hormone-releasing
hormone receptor (GHRH-R) (Matsuno et al. 1999; Sanno
et al. 1997). Pituitary adenomas sometimes express more
than one or two hormones. In our series, about 80% of
GHomas are positive for PRL, and 56% of them are posi-
tive for SU. Therefore, GHomas are plurihormonal
tumors. Occasionally, GHomas also produce ACTH, which
belongs to a diVerent lineage, in the same tumor cells. For
the molecular mechanism, aberrant combination of tran-
scription factors has been proposed (Osamura et al. 2004).
Some speciWc genes have been identiWed that predispose
the hereditary pituitary adenomas. The multiple endocrine
neoplasia (MEN1) gene, a tumor suppressor, is located on
chromosome 11q13 frequently associated with GHoma and
PRLoma (Chandrasekharappa et al. 1997). Somatic muta-
tions in the -subunit of the Gs protein, which led to a con-
stitutive activation of adenylyl cyclase, are reported in
about 40% of GH-producing pituitary adenomas (Landis
et al. 1990).
PRL producing (cell) adenomas (PRLomas)
General Wndings
The tumor cells are classically chromophobic and immuno-
histochemically contain condensed PRL in the Golgi
regions near the nuclei (Nebenkern; Golgi pattern)
(Fig. 7a–b). PRLomas are usually mono-hormonal. No
other hormones are detected by IHC. By electron micro-
scope (EM), the tumor cells contain prominent Golgi sac-
cules and a few small NSGs (Fig. 7c). Clinically, they are
associated with manifestation due to the prominent increase
in serum PRL levels (hyperprolactinemia) which are usu-
ally parallel to the tumor size. They can be electron micro-
scopically classiWed into sparsely granulated and densely
granulated type. The most frequent tumor type is sparsely
granulated and they usually show high response to dopa-
mine agonists (Al-Brahim and Asa 2006). Calcospherites or
psammoma bodies are sometimes found (DeLellis et al.
2004). Densely granulated adenoma is rare, and is
Fig. 6 The IHC of CAM 5.2 
keratin (CK8). In some GHo-
mas, the tumor cells shows glob-
ules of keratin, which are called 
as Wbrous bodies, by IHC (a). b 
Shows magniWed image of dot 
type Wbrous bodies. In granu-
lated adenomas, keratin is 
immunostained in cytoplasm (c). 
In electron microscopy, Wbrous 
bodies shows smooth endoplas-
mic reticulum located in the Gol-
gi region (d)500 Histochem Cell Biol (2008) 130:495–507
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composed of acidophilic to chromophobic cells with abun-
dant and diVuse cytoplasmic PRL granules. Clinically, GH-
PRL adenomas with the exception of acidophil stem cell
adenomas are also characterized by hyper prolactinemia.
SpeciWc Wndings
Immunohistochemical staining of the “Golgi pattern” is
quite unique. Electron microscopically, the extrusion of
secretary granules along the lateral cell surfaces into the
extracellular space, so-called “misplaced exocytosis”, has
been regarded as a speciWc feature of the sparsely granu-
lated PRLoma (DeLellis et al. 2004; Vidal et al. 2004) .
Changes induced by Bromocriptine
In the tumors from the patients with eVective treatment by a
dopamine agonist, Bromocriptine (BC), the tumor cells
contain accumulated secretory granules. The induction of
adenoma cells shrinkage and marked decrease in serum
PRL level were observed in BC treatment (Kovacs and
Horvath 2005). It has also been reported that BC induces
exocytosis of the granules though there was a reduction in
serum PRL revels (Mori et al. 2001).
Molecular Wndings
It has been reported that most PRLomas are immunohisto-
chemcially positive for Pit-1 and estrogen receptor (ER).
The binding sites for Pit-1 and ER are close enough to syn-
ergize for the production of PRL. PRL cells are of extreme
diVerentiation and most PRLomas are mono-hormonal.
Recently, the pituitary tumor transforming gene (PTTG)
has been suggested to be expressed in high levels in diVer-
ent pituitary tumor and to play a central role in pituitary
tumorigenesis (Yu and Melmed 2004). The role of PTTG in
prolactinomas is not clear but PTTG might involve lacto-
troph angiogenesis in pituitary adenomas in correlation
with the increase in estrogen action (Cristina et al. 2007).
ACTH producing (cell) adenomas (ACTHomas)
General Wndings
ACTH producing adenomas with Cushing’s disease repre-
sent 10–15% of pituitary tumors (Trouillas 2002). Most
tumors are microadenomas with the cells which are baso-
philic and strongly PAS-positive (Saeger et al. 2007). The
tumor consists of monomorphic round cells arranged
diVusely with a sinusoidal pattern (Robert and Hardy
1986). Some tumors are chromophobic and weakly PAS-
positive. By IHC, these tumors are immunoreactive for
ACTH, -LPH and/or -endorphin. The intensity of hor-
mone immunoreactivity varies: basophilic adenomas tend
to be strongly positive. In the presence of active ACTH
producing adenomas, the non neoplastic coritotropes often
show characteristic alterations in Crooke’s cells. These
cells are larger than normal ACTH cells and exhibit an
interacytoplasmic hyaline ring (Crooke 1935).
Fig. 7 PRL producing (cell) 
adenoma (PRLoma). The tumor 
cells of hematoxylin eosin 
(H&E) staining (a) and IHC of 
PRL, which shows condense in 
the Golgi regions near the nuclei 
(b). In electron microscopy, 
prominent Golgi saccules and a 
few small NSGs are seen (c). 
d shows the extrusion 
of secretory granules, 
so called “misplaces exocytosis”Histochem Cell Biol (2008) 130:495–507 501
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SpeciWc Wndings
Silent ACTH producing adenoma
ACTH producing adenomas without clinical and/or biolog-
ical signs of hypercorticolism may be discovered by the
pathologist, is named as silent ACTH producing adenoma
(Horvath et al. 1980; Lloyd et al. 1997). Some of them
secrete high molecular weight ACTH (Reincke et al. 1987).
The silent densely granulated ACTH adenoma is desig-
nated as subtype 1 adenoma (Kovacs and Horvath 1986).
The second inactive is the sparsely granulated adenoma and
is called subtype 2 adenoma. They are large, frequently
invasive into the cavernous sinus and sphenoid sinus.
Crooke’s cell adenoma
Corticotroph adenomas generally do not undergo Crooke’s
hyaline change. Nonetheless, rare adenomas composed of
Crooke’s cells are described as the Crooke’s cell adenoma
(Franscella et al. 1991). In H&E staining sections, the cells
were characterized by densely eosinophilic and hyaline
cytoplasm (Fig. 8a). The hyaline material was strongly
cytokeratin immunoreactive (Fig. 8c). EM showed the
accumulation of intermediate Wlaments was massive
(Fig. 8d). Compared with typical corticotroph adenomas,
Crooke’s cell adenomas are clinically aggressive. It typi-
cally presents as an invasive macroadenoma. In recent
study, invasiveness was found in 72% of this adenoma.
They have a higher rate of recurrence than other cortico-
troph adenomas (George et al. 2003).
Molecular Wndings
In ACTH producing adenoma, the transcription factor Neu-
roD1 (Oyama et al. 2001) and Tpit (Lamolet et al. 2001)
are positive. The tumor cells produce prohormone, proopio-
melanocortin (POMC), from which ACTH is derived after
proper proteolytic digestion by prohormone convertase
(PC1/3). When PC2 is present, -melanotroph stimulating
hormone (MSH) is positive in the adenoma cells.
TSH producing (cell) adenomas (TSHomas)
General Wndings
TSH producing adenomas are not frequent (Bertholon-
Gregoire et al. 1999). The patients with TSHomas are fre-
quently hyperthyroid presenting Graves’ disease. Some-
times, the patients show high serum GH level or PRL level.
The tumor is usually macroadenoma as with extensive
invasion. The tumors are composed of choromophobic cells
and exhibit sinusoidal growth pattern (Fig. 9a). By IHC, the
tumor cells are positive for TSH and SU. The tumors are
also sometimes multihormonal with positive staining for
GH and PRL (Sanno et al. 1994, 1995). Electron micro-
graphs of the adenoma, show that the tumor cells were
Fig. 8 Crooke cell adenoma. 
The Crooke cell adenoma of 
hematoxylin eosin (H&E) stain-
ing, which is characterized by 
densely eosinophilic and hyaline 
cytoplasm (a). The IHC of 
ACTH (b). c Shows the image of 
CAM 5.2 (keratin) immuno-
staining. Electron microscopy 
showed the accumulation of 
massive intermediate Wlaments 
(asterisk) (d)502 Histochem Cell Biol (2008) 130:495–507
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elongated and manifested with long cytoplasmic processes
and round or ovoid nuclei with prominent nucleoli. There
was a moderate development of rough endoplasmic reticu-
lum and Golgi complexes. Small secretory granules mea-
suring between 50 and 200 nm tend to accumulate along
the cell membrane (Teramoto et al. 2004).
SpeciWc Wndings
It has been pointed out by neurosurgeons that TSHomas are
Wrm on their operation. By histology, the tumors frequently
exhibit stromal Wbrosis of various amounts among the
tumor cells (Fig. 9b). Ocasional psammoma bodies are also
observed.
Molecular Wndings
The tumors are multihormonal with the concomitant pro-
duction of TSH, GH and PRL (Fig. 10a–c). As transcription
factors, Pit–1 (Fig. 10d) and GATA-2 (Fig. 10e) have been
synergistic for the production of TSH. Pit-1 also regulates
GH and PRL.
Gonadotropin producing adenomas
FSH producing adenomas (FSHomas)
General Wndings
Light microscopically, this type of tumors shows frequent
unique morphology by H&E staining which is character-
ized by many chromophobic spindle cells arranged in
“pseudorosette” patterns (Fig. 11c). Immunohistochemi-
cally, the tumor cells are frequently positive for FSHSU
and SU (Fig. 11d–e). LHSU is seldom positive. By EM,
the tumor cells show small secretory granules in the cyto-
plasm along with cell membrane.
Fig. 9 TSH producing (cell) 
adenoma (TSHoma). The tumor 
cell of hematoxylin eosin (H&E) 
staining (a). It is clearly showed 
by Heidenhain’s azan stain, the 
stromal Wbrosis in tumors (b)
Fig. 10 IHC of TSH (TSHoma). It shows many TSH positive tumor cells (a), and multihormonal with the concominant production of PRL (b)
and GH (c). For transcription factors, Pit-1 (d) and GATA-2 (e) are positive and sometimes ER (f) is positiveHistochem Cell Biol (2008) 130:495–507 503
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SpeciWc Wndings
The above pseudorosette pattern is speciWc for this type
of tumors. It is of particular interests that most FSHomas
occur in male patients. Activin-signaling in male mouse
gonadotropes may be diVerent from the female-type
gonadotropes. In male mouse pituitary cells, Smad
stimulated expression of gonadotropins includes LH
and FSH through the activin-signaling (Coss et al.
2005).
Gonadotropin subunits (SUs) producing adenomas 
(Gn-omas)
General Wndings
The nonfunctional pituitary adenomas have been shown to
be derived from gonadotroph cells. And thus, almost all
nonfunctional pituitary adenomas are termed Gn-omas.
These tumors represent a half of all macroadenomas and
present clinically in patients with visual Weld loss, head-
aches, hypogonadism, and hypopituitarism (Fig. 12a–b).
The tumors are mostly chromophobic and are composed of
smaller pituitary cells.
SpeciWc Wndings
Chromophobe cells without apparent pseudorosette patterns
are speciWcally suggestive of Gn-omas. Focally, pseudorosette
pattern is also observed. By IHC, about 40% of the tumors are
positive for FSHSU and SU. LHSU is less frequent. It has
been claimed that diVerent tumor cells are positive for SU
and SU which account for the lack of speciWc function of
FSH (Fig. 9c–d). Gn-omas with markedly increased mitochon-
dria in the cytoplasm have been designated as oncocytomas.
Molecular Wndings
Most gonadotropinoma show FSHSU and SU. Fre-
quently, the tumors are also positive for TSHSU. The tran-
scription factor steroidogenic factor-1 (SF-1) has been
speciWc for gonadotropin production (Fig. 11f) (Asa et al.
1996). GATA-2 is an another transcription factor which syn-
ergizes with SF-1 to produce of TSH (Dasen et al. 1999).
Fig. 11 FSH producing (cell) 
adenoma (FSHoma). The tumor 
cells were organized into pseu-
dorosette patterns (a). About 
40% of FSHomas are immuno-
positive for SU (b), FSHSU 
(c) and SF-1 (d). In contrast, 
LHSU immunoreactivity is 
rare504 Histochem Cell Biol (2008) 130:495–507
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Null cell adenomas
General Wndings
When the tumor cells are immuno-negative for any pitui-
tary hormones, the tumors have been designated as “null
cell adenomas”.
SpeciWc Wndings
These types of adenomas includes chromophobic acido-
philic or partly chromophobic, partly acidophilic with a
diVuse pattern and elongated small cells forming psuedoro-
settes around the markedly dilated capillaries. Since some
gonadotroph adenomas share the ultrastructural features of
null cell adenomas, it is tempting to consider the latter as
originating in a gonadotroph. The cells of null cell adenoma
show a modest cytoplasm with poorly developed rough
endoplasmic reticulum and Golgi apparatus, and rare round
secretary granules, measuring up to 250 nm (Horvath and
Kovacs 1984).
Plurihormonal adenomas
Silent subtype 3 adenoma
Silent subtype 3 adenomas are rare pituitary tumors that
have immunoreactivities for more than one pituitary hor-
mone. They are classiWed as unusual pulrihormonal adeno-
mas in the World Health Organization (WHO) ClassiWcation
of Endocrine Tumors (DeLellis et al. 2004). Silent subtype 3
adenomas are described by Horvath et al. (1980) for the Wrst
time from the ultrastructural characteristics.
Although they have much variation in terms of histology
and IHC, the ultrastructures have been characteristic and
diagnostic.
Clinical features
At the time of diagnosis, these tumors are usually macroad-
enomas. They are usually associated with hyperprolactine-
mia and often clinically mistaken for prolactinomas and
treated especially in women. They sometimes display
aggressive behavior with suprasellar or parasellar extension
and also have a high recurrence rate. Complete surgical
removal is sometimes diYcult and the radiotherapy is done
in postoperative management (Horvath et al. 1988).
Pathology
The adenoma cells are middle-sized or large, and polar. The
euchromatic nuclei contain large prominent nucleolus and
often a few fragments of nuclear inclusions (Spheridia)
whose function is unknown. Nuclear spheria are not spe-
ciWc for subtype 3 adenoma, but abundant spheria are char-
acteristic of the tumors (Horvath et al. 1988). The ample
cytoplasm contains extensively distributed rough-surfaced
endoplasmic reticulum, randomly distributed smooth-sur-
faced endoplasmic reticulum and large tortuous Golgi com-
plex. The secretory granules of about 100–200 nm are
numerous and tend to accumulate heavily in cell processes,
which is a typical feature of glycoprotein hormone cell
diVerentiation (Horvath et al. 2005). Immunohistochemi-
cally, the tumor cells are immunoreactive for mainly GH,
PRL and TSH. However, they also have other varied
combination of hormones and their cytogenesis remains
unresolved.
Pituitary adenomas with “translineage” diVerentiation
Very occasionally, some human pituitary tumors demon-
strate their functional diVerentiation toward the production
of hormones belonging to diVerent cell lineages, i.e.,
Fig. 12 Gonadotropin producing (cell) adenoma (Gn-oma). Mid-sagittal (a) and coronal (b) MRI image. The tumor cells present macroadenoma
type and no evidence of bioactivities of hormone. SU (c, d; blue), FSHSU (c; brown) and LHSU (d; brown) are localized in diVerent tumor cellsHistochem Cell Biol (2008) 130:495–507 505
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ACTHomas with GH production, GHomas with ACTH
production, FSHomas with ACTH production and so on.
We have studied the cases of ACTHomas with GH
production and GHomsa with ACTH production. These
cases demonstrate both NeuroD1 and Pit-1 transcription
factors in the tumor cells could induce “translineage”
diVerentiation. We have postulated that “aberrant”
expressions of transcription factors could be the cause of
this abnormal diVerentiation in the tumors (Tahara et al.
2002).
Pituitary adenomas with only early diVerentiation
Some ACTHomas have been shown to be positive for
ACTH and also positive for SU in the tumor cells. Five of
89 cases of ACTHomas showed this aberrant expression. In
human pituitaries, it has been suggested that ACTH appears
as a Wrst hormone proceeding to SU (Osamura, personal
observation by IHC). In human, two distinct diVerentiation
pathways exist: (1) ACTH lineage and (2) gonado–GH–
PRL–TSH lineage.
These tumors only exhibiting ACTH and SU are of par-
ticular interests in considering their histogenesis. These
tumors are considered to be derived from the primitive pitu-
itary ACTH committed progenitor cells with aberrant
expression of SU. Detailed mechanisms remained to be
further investigated (Suzuki et al. 2008).
Special types of pituitary adenomas and carcinomas
Even though the incidence is very rare, we see some cases
of the very unique and special cases of the pituitary tumors.
For this situation, IHC and molecular analysis are expected
to play key roles in establishing diagnosis.
Ectopic pituitary adenomas
It has been well documented that the pituitary adenomas
can occur outside of sella turcica, most frequently in the
sphenoid sinuses. The diVerential diagnoses contain olfac-
tory neuroblastoma (esthesioneuroblastomas), rhabdo-
myosaromas and germinomas. The establishment of the
proper diagnosis relies on immunohistochemical Wndings
including neuroendocrine markers such as chromogranin A,
synaptophysin and SNAP25 as well as some pituitary hor-
mones. Especially, the detection of the pituitary hormones
is diagnostic for this lesion (Fig. 13). 
Invasive pituitary adenomas
Some intra-sellar pituitary adenomas can grow downward
and invade the sphenoid sinuses. Various types of adeno-
mas can present this growth pattern. A case of acute menin-
gitis induced by invasive pituitary PRLomas has been
reported as an autopsy case with a very short clinical his-
tory (Onoda et al. 1992).
Pituitary carcinomas
A few cases of pituitary carcinomas have been reported in
the literature. Frequently, the pituitary carcinomas demon-
strate liver metastasis. The tumor cells are more atypical
than usual adenomas and show high MIB-1 proliferative
indices. The tumors are frequently functioning, such as
PRL producing or ACTH producing.
Gangliocytoma
This is a very rare tumor, which has been reported as a
source for GHRH which stimulates hyperplastic GH cells
(Kurosaki et al. 2002) (Fig. 14). 
Fig. 13 H&E staining of the 
tumor cells (a). Neuroendocrine 
marker SNAP25 (b) and 
pituitary hormone FSH (c) 
and ACTH (d) are detected. 
e Electron microscopy shows 
dense cored secretory granules506 Histochem Cell Biol (2008) 130:495–507
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Metastatic carcinomas
The metastatic carcinomas in the pituitary region retain the
morphologic features of the primary tumors or those of
other metastatic sites. Primary lung cancer, especially the
small cell carcinoma, has been experienced as a primary
source of the metastatic carcinomas to the pituitary.
PRLomas with Germinomas
It is very rare occasion to see germinoma as an intra-sellar
tumor. Morphologically, the tumor cells demonstrate typi-
cal features similar to testicular seminomas or ovarian dys-
germinomas. A reported case of germinoma showed
admixed foci of PRLomas (Sugiyama et al. 1999). The
morphogenesis of this “mixed” tumor remains to be further
investigated.
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